Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-part Phase I Study With the Antibody-drug Conjugate SYD985 in Combination With Niraparib to Evaluate Safety, Pharmacokinetics and Efficacy in Patients With HER2-expressing Locally Advanced or Metastatic Solid Tumors.

NCT04235101 is registered in ClinicalTrials.gov with Byondis B.V. as lead sponsor.

NCT NCT04235101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04235101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-part Phase I Study With the Antibody-drug Conjugate SYD985 in Combination With Niraparib to Evaluate Safety, Pharmacokinetics and Efficacy in Patients With HER2-expressing Locally Advanced or Metastatic Solid Tumors.
Lead sponsor
Byondis B.V.
Phase
Phase 1
Overall status
Completed
Start date
June 22, 2020
Completion date
April 24, 2023
Enrollment
32 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor